{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-058628","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.971663+00:00","generated_at":"2026-06-25T21:14:14.144158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvectis Pharma Q1 net loss $2.9M; cash $16.7M; NXP800 Phase 1 dose escalation ongoing","bullets":["Net loss of $2.9M for Q1 2022, including $0.2M non-cash expense.","Cash, cash equivalents and short-term investments of $16.7M at March 31, 2022, up from $5.7M at Dec 31, 2021 due to IPO.","R&D expenses $1.8M; G&A expenses $1.1M for the quarter.","NXP800 Phase 1 dose escalation portion ongoing; presented at 2022 AACR 'New Drugs on the Horizon'.","Completed IPO in Feb 2022 raising $16M gross proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-058628","json":"https://secwatch.observer/filing/0001104659-22-058628.json","markdown":"https://secwatch.observer/filing/0001104659-22-058628.md","text":"https://secwatch.observer/filing/0001104659-22-058628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922058628/0001104659-22-058628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922058628/tm2214978d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:14:14.144158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}